College of Medicine – Phoenix leads the way in Addiction Medicine through unique fellowship. Continue reading
Author Archive: AZBio
New Study Makes Important Step Toward Treatment of Deadly Brain Cancer
A new Ivy Brain Tumor Center study finds that recently-approved drug ribociclib may be an important part of treatment for glioblastoma, one of the deadliest cancers in the world.Continue reading
ASU researchers use single cell droplet technology to find cause of cancer mutations
Five years in the making, researchers at ASU are still on the search to find what causes triple negative cancerContinue reading
UA Researchers Make Next Move in Fight Against Ovarian Cancer A little scope with big impact could increase survival rates for cancer patients.
With a $863,000, three-year grant from the United States Army, Jennifer Barton, director of the BIO5 Institute and professor of biomedical engineering, biosystems engineering,electrical and computer engineering and optical sciences, is continuing her research into a disposable falloposcope to detect early-stage ovarian cancer. A falloposcope is an endoscope used to image the fallopian tubes, where researchers now believe ovarian cancer originates.Continue reading
TGen North partners with NARBHA Institute to promote human health
‘TGen One Health Collaborative’ uses holistic approach to connect human health and the environmentContinue reading
National Cancer Institute awards Carlo Maley $10.8M grant
Carlo Maley, associate professor in the Biodesign Center for Biocomputing, Security and Society and director of the Arizona Cancer Evolution Center, was selected as a recipient of a $10.8M grant from the National Cancer Institute. The Breast Pre-Cancer Atlas will be an active repository for information about breast tumors, open to the scientific community to use for further analysis.Continue reading
INSYS Therapeutics Announces Results Of PK Study Assessing Proprietary Intranasal Naloxone Formulations Versus Intramuscular And Intravenous Naloxone For Opioid Overdose
INSYS Therapeutics, Inc. (NASDAQ: INSY), announced om November 1, 2018 that a pharmacokinetic (PK) study (INS012-18-119) of its proprietary intranasal naloxone spray formulations for the treatment of opioid overdose showed a distinctive PK profile compared to the current standards of intramuscular (IM) and intravenous (IV) administration of naloxone.
Honoring Our AZBio Veterans – Veterans Day 2018
Each Year AZBio extends an opportunity to all member companies to tell us about the veterans on their team. This video is our tribute to them and to all who have served. Continue reading